Price
$134.98+0.70%Social Signal Score
Analyst Ratings
29 analystsRevenue
$570.33M+25.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Weidman
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 15,500
- Beta
- 0.81
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.93
Financials
Revenue
$570.33M+25.2%Net Income
$102.02M+53.8%EBITDA
$73.09M-37.2%Free Cash Flow
$114.73M+10.9%EPS (diluted)
$2.28+62.9%Shares Outstanding (diluted)
43.66M-8.0%Operating Expenses
$258.64MCash & Debt
$300.16MReturn of Capital
$260.15MRevenue by Segment (annual)
$1.99BDividend per Share
$0.34Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.99B | $-905.64M | $-20.30 |
| 2024 | $3.05B | $69.67M | $1.49 |
| 2023 | $2.97B | $356.33M | $7.58 |
| 2022 | $2.79B | $363.14M | $7.74 |
| 2021 | $2.81B | $485.37M | $10.38 |
| 2020 | $2.54B | $335.32M | $7.21 |
| 2019 | $2.60B | $461.47M | $9.99 |
| 2018 | $2.45B | $200.80M | $4.39 |
| 2017 | $2.15B | $152.53M | $3.39 |
| 2016 | $1.87B | $237.38M | $5.48 |
| 2015 | $1.81B | $244.86M | $5.89 |
| 2014 | $1.84B | $187.68M | $4.54 |
| 2013 | $1.70B | $150.88M | $3.67 |
| 2012 | $1.55B | $-190.06M | $-4.65 |
Valuation
TFXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+100.00%Social Signal Score
Mentions (17)
- Newsbusinesswire.com·7d ago·Neutral
… Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central …
View source ↗ - Newszacks.com·7d ago·Neutral
Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock? Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
View source ↗ - Newszacks.com·24d ago·Neutral
TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
View source ↗ - News (RSS)yahoo·32d ago·Positive
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push
View source ↗ - News (Marketaux)insidermonkey.com·32d ago·Positive
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push On August 6, Teleflex Incor[+302 characters]
View source ↗ - Newsbusinesswire.com·32d ago·Negative
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technolog…
View source ↗ - Newszacks.com·39d ago·Neutral
Should You Add Teleflex Stock to Your Portfolio Now? TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
View source ↗ - Newszacks.com·40d ago·Positive
TFX or PEN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newszacks.com·41d ago·Positive
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain? Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
View source ↗ - Newszacks.com·42d ago·Negative
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns? TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.
View source ↗ - News (RSS)seekingalpha·43d ago·Positive
Teleflex: Strong Company Undergoing Messy Transition, Hold
View source ↗ - News (Marketaux)seekingalpha.com·43d ago·Positive
Teleflex: Strong Company Undergoing Messy Transition, Hold (NYSE:TFX) Teleflex Incorporated [+307 characters]
View source ↗ - News (RSS)seekingalpha·44d ago·Neutral
Teleflex: Portfolio Surgery Creates A Better Medtech Compounder
View source ↗ - Newsseekingalpha.com·44d ago·Negative
…r Teleflex is transforming into a focused procedural technology platform, divesting lower-growth units and reinvesting in high-acuity Vascular and Surgical segments. TFX's Vascular and Surgical segments are generating high-single-digit growth, while Interventional segment weakness is attributed to temporary integration challenges. Proceeds from divestitures are funding debt reduction and substantial share repurchases, enhancing per-share earnings potential and financial flexibility.
View source ↗ - Newszacks.com·56d ago·Neutral
TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·56d ago·Neutral
Why Teleflex (TFX) International Revenue Trends Deserve Your Attention Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Teleflex Q2 Earnings Call Highlights Teleflex NYSE: TFX reported second-quarter revenue and adjusted earnings above its expectations, supported by strong growth in its Vascular and Surgical businesses, while slower-than-anticipated integration of its acquired Vascular Intervention business weighed on Interventional results.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.90 per share
Typical surprise +8.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.76 vs $1.28beat
- Thu, May 7$1.39 vs $1.21beat
- Thu, Feb 26$1.93 vs $3.73miss
- Thu, Nov 6$3.67 vs $3.38beat
- Thu, Jul 31$3.73 vs $3.36beat
- Thu, May 1$2.91 vs $2.88beat
Estimates and results for TFX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TFX officers and directors.
- Bought
- $634k
- Sold
- —
6 trades
0 trades
- Haggerty Gretchen Rbought
- Haggerty Gretchen Rbought
- Randle Stuart Abought
- Krakauer Andrew Abought
- Kelly Liambought
- Ryu Jaewonbought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (28d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (8d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Buy$15,001 - $50,000
- Susie Leehouse · NV03 · disclosed Dec 29, 2022 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (38d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (36d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 8, 2022 (28d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jul 13, 2021 (15d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (34d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (26d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 11, 2021 (39d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jun 15, 2020 (48d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jun 15, 2020 (27d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Jan 16, 2020 (20d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.